DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells As well as in cells missing functional p53 either on your own or in combination with tamoxifen, when the effectiveness of ABBV-744 was